At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 11, 2026 at 16:15 ET
Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.
- Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
- Underwriters exercised option in full for an additional 581,199 shares
- Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
- Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access